SG175133A1 - Methods of treating edema related to ischemia-reperfusion - Google Patents

Methods of treating edema related to ischemia-reperfusion Download PDF

Info

Publication number
SG175133A1
SG175133A1 SG2011073475A SG2011073475A SG175133A1 SG 175133 A1 SG175133 A1 SG 175133A1 SG 2011073475 A SG2011073475 A SG 2011073475A SG 2011073475 A SG2011073475 A SG 2011073475A SG 175133 A1 SG175133 A1 SG 175133A1
Authority
SG
Singapore
Prior art keywords
tissue
compound
ischemia
transplant
reperfusion
Prior art date
Application number
SG2011073475A
Other languages
English (en)
Inventor
Thomas Michael Egan
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of SG175133A1 publication Critical patent/SG175133A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
SG2011073475A 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion SG175133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16808909P 2009-04-09 2009-04-09
PCT/US2010/030556 WO2010118334A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Publications (1)

Publication Number Publication Date
SG175133A1 true SG175133A1 (en) 2011-12-29

Family

ID=42936599

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011073475A SG175133A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Country Status (14)

Country Link
US (1) US20120064044A1 (cg-RX-API-DMAC7.html)
EP (1) EP2416651A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012523432A (cg-RX-API-DMAC7.html)
KR (1) KR20120005025A (cg-RX-API-DMAC7.html)
CN (1) CN102458113A (cg-RX-API-DMAC7.html)
AU (1) AU2010233151A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2757998A1 (cg-RX-API-DMAC7.html)
EA (1) EA201101349A1 (cg-RX-API-DMAC7.html)
IL (1) IL215604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011010616A (cg-RX-API-DMAC7.html)
SG (1) SG175133A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010118334A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107815B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126822A2 (en) 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2021097345A1 (en) * 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05139992A (ja) * 1991-11-13 1993-06-08 Ajinomoto Co Inc ヒトadfを含有する臓器保護剤
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2004085396A1 (ja) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
AU2008285626B2 (en) * 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
WO2009126822A2 (en) * 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation

Also Published As

Publication number Publication date
KR20120005025A (ko) 2012-01-13
AU2010233151A1 (en) 2011-11-17
BRPI1010516A2 (pt) 2015-08-25
EA201101349A1 (ru) 2012-05-30
MX2011010616A (es) 2012-03-14
EP2416651A1 (en) 2012-02-15
CA2757998A1 (en) 2010-10-14
US20120064044A1 (en) 2012-03-15
WO2010118334A1 (en) 2010-10-14
JP2012523432A (ja) 2012-10-04
EP2416651A4 (en) 2014-03-26
ZA201107815B (en) 2013-04-24
IL215604A0 (en) 2011-12-29
CN102458113A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
US20120064044A1 (en) Methods of treating edema related to ischemia-reperfusion
Moskowitzova et al. Mitochondrial transplantation prolongs cold ischemia time in murine heart transplantation
CA2659542C (en) Methods and compositions for inhibiting angiogenesis
Hou et al. Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis
Li et al. Bone marrow‐derived mesenchymal stem cells enhance autophagy via PI 3K/AKT signalling to reduce the severity of ischaemia/reperfusion‐induced lung injury
US11633424B2 (en) Cell protective methods and compositions
JP2020536048A (ja) 発毛を調節するための組成物及び方法
US8809303B2 (en) Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
Ta et al. Steen solution protects pulmonary microvascular endothelial cells and preserves endothelial barrier after lipopolysaccharide-induced injury
CN114599379A (zh) 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法
US20260069634A1 (en) Pharmaceutical composition, for preventing or treating hearing loss or tinnitus, comprising mitochondria as active ingredient
CN115518158B (zh) mTOR抑制剂体外诱导树突状细胞及其应用
JP2022083279A (ja) 腎臓保護用の組成物
US20240423969A1 (en) Synergistic drug combinations to treat cancer
US6313104B1 (en) Organoprotective solutions
Choi Effect of Remote Ischemic Conditioning on Lipopolysaccharide-induced Pulmonary Inflammation
Walkup et al. Endothelial cell impact on adult derived hepatic progenitor cells
Watts III et al. Monophosphoryl lipid A prevents impairment of medullary thick ascending LIMB 4 HCO3-absorption and improves plasma HCO3-concentration in septic mice 5
Yu et al. Chaofeng Hu1, Daxiang Lu1, Ben Lv2 & Huadong Wang1
CN103989701A (zh) 聚乙二醇4000或聚乙二醇6000在制备预防或治疗水母毒素心脏毒性药物中的应用